{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(16)"],"submitter":["Bassan R"],"pubmed_abstract":["Pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/LL). In LAL1913 trial, the Gruppo Italiano Malattie EMatologiche dell'Adulto added pegaspargase 2000 IU/m2 to courses 1, 2, 5, and 6 of an 8-block protocol for patients aged from 18 to 65 years, with dose reductions in patients aged >55 years. Responders were risk stratified for allogeneic hematopoietic cell transplantation (HCT) or maintenance per clinical characteristics and minimal residual disease (MRD). Of 203 study patients (median age, 39.8 years), 91% achieved a complete remission. The 3-year overall survival, event-free, and disease-free survival (DFS) rates were 66.7%, 57.7%, and 63.3%, respectively, fulfilling the primary"],"journal":["Blood advances"],"pagination":["4448-4461"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10440455"],"repository":["biostudies-literature"],"pubmed_title":["Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial."],"pmcid":["PMC10440455"],"pubmed_authors":["Chiaretti S","Della Starza I","Paoloni F","Guarini A","Piciocchi A","De Propris MS","Bonifacio M","Foa R","Mattei D","Candoni A","Mauro E","Borlenghi E","De Fabritiis P","Marbello L","Vitale A","Cassibba V","Bassan R","Messina M","Santoro A","Elia L","Bocchia M","Rambaldi A","Audisio E","Latte G","Spinelli O","Martinelli G","Trappolini S","Scattolin AM","Zappasodi P","Di Bartolomeo P","Fazi P","Fracchiolla N"],"additional_accession":[]},"is_claimable":false,"name":"Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.","description":"Pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/LL). In LAL1913 trial, the Gruppo Italiano Malattie EMatologiche dell'Adulto added pegaspargase 2000 IU/m2 to courses 1, 2, 5, and 6 of an 8-block protocol for patients aged from 18 to 65 years, with dose reductions in patients aged >55 years. Responders were risk stratified for allogeneic hematopoietic cell transplantation (HCT) or maintenance per clinical characteristics and minimal residual disease (MRD). Of 203 study patients (median age, 39.8 years), 91% achieved a complete remission. The 3-year overall survival, event-free, and disease-free survival (DFS) rates were 66.7%, 57.7%, and 63.3%, respectively, fulfilling the primary","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-04-12T23:07:39.265Z","creation":"2025-02-19T00:38:16.596Z"},"accession":"S-EPMC10440455","cross_references":{"pubmed":["37276451"],"doi":["10.1182/bloodadvances.2022009596"]}}